SKYE vs SLS

Skye Bioscience, Inc. vs SELLAS Life Sciences Group, Inc — Valuation Comparison 2026

SKYE

Biotechnology
Skye Bioscience, Inc.
Quality
3.6
out of 10
Value Trap
30
LOW
Price
$0.85
Last close
Models
7/13
Active
VS

SLS

Biotechnology
SELLAS Life Sciences Group, Inc
Quality
4.1
out of 10
Value Trap
18
SAFE
Price
$9.18
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SKYE Fair ValueSKYE Upside SLS Fair ValueSLS Upside
Bayesian DCF Intrinsic $0.21 -74.8% $2.78 -69.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.84 +116.7% $0.65 -92.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SKYE vs SLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SKYE vs SLS — Which Stock Is More Undervalued?

SLS scores higher with a 4.1/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Skye Bioscience, Inc. (SKYE) and SELLAS Life Sciences Group, Inc (SLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SKYE currently trades at $0.85 with a QOC of 3.6/10, while SLS trades at $9.18 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).